Enhanced antibody half-life improves in vivo activityJonathan Zalevsky, John R. Desjarlais, Aaron K. Chamberlain et al.|Nature Biotechnology|2010Cited by 654
The impact of Fc engineering on an anti-CD19 antibody: increased Fcγ receptor affinity enhances B-cell clearing in nonhuman primatesJonathan Zalevsky, Chris E. Lawrence, Seung Y. Chu et al.|Blood|2008Cited by 101
Engineering Fully Human Monoclonal Antibodies from Murine Variable RegionsMatthew J. Bernett, Greg A. Lazar, Sher Karki et al.|Journal of Molecular Biology|2010Cited by 52
XmAb™2513, an Fc Engineered Humanized Anti-CD30 Monoclonal Antibody, Has Potent In Vitro and In Vivo Activities, and Has the Potential for Treating Hematologic Malignancies.Chris E. Lawrence, David F. Carmichael, Phil W. Hammond et al.|Blood|2007Cited by 11
XmAb®5574, An Fc Engineered Humanized Anti-CD19 Monoclonal Antibody, Has Potent in Vitro and in Vivo Activities, and Has the Potential for Treating B Cell MalignanciesChris E. Lawrence, David F. Carmichael, Jonathan Zalevsky et al.|Blood|2008Cited by 1